Cargando…

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Cao, Maria, Puertolas, Teresa, Riveiro, Mar, Muñoz-Couselo, Eva, Ortiz, Carolina, Paredes, Roger, Podzamczer, Daniel, Manzano, Jose Luis, Molto, Jose, Revollo, Boris, Carrera, Cristina, Mateu, Lourdes, Fancelli, Sara, Espinosa, Enrique, Clotet, Bonaventura, Martinez-Picado, Javier, Cerezuela, Pablo, Soria, Ainara, Marquez-Rodas, Ivan, Mandala, Mario, Berrocal, Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009216/
https://www.ncbi.nlm.nih.gov/pubmed/33782108
http://dx.doi.org/10.1136/jitc-2020-001664
_version_ 1783672837040504832
author Gonzalez-Cao, Maria
Puertolas, Teresa
Riveiro, Mar
Muñoz-Couselo, Eva
Ortiz, Carolina
Paredes, Roger
Podzamczer, Daniel
Manzano, Jose Luis
Molto, Jose
Revollo, Boris
Carrera, Cristina
Mateu, Lourdes
Fancelli, Sara
Espinosa, Enrique
Clotet, Bonaventura
Martinez-Picado, Javier
Cerezuela, Pablo
Soria, Ainara
Marquez-Rodas, Ivan
Mandala, Mario
Berrocal, Alfonso
author_facet Gonzalez-Cao, Maria
Puertolas, Teresa
Riveiro, Mar
Muñoz-Couselo, Eva
Ortiz, Carolina
Paredes, Roger
Podzamczer, Daniel
Manzano, Jose Luis
Molto, Jose
Revollo, Boris
Carrera, Cristina
Mateu, Lourdes
Fancelli, Sara
Espinosa, Enrique
Clotet, Bonaventura
Martinez-Picado, Javier
Cerezuela, Pablo
Soria, Ainara
Marquez-Rodas, Ivan
Mandala, Mario
Berrocal, Alfonso
author_sort Gonzalez-Cao, Maria
collection PubMed
description Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.
format Online
Article
Text
id pubmed-8009216
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-80092162021-04-16 Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) Gonzalez-Cao, Maria Puertolas, Teresa Riveiro, Mar Muñoz-Couselo, Eva Ortiz, Carolina Paredes, Roger Podzamczer, Daniel Manzano, Jose Luis Molto, Jose Revollo, Boris Carrera, Cristina Mateu, Lourdes Fancelli, Sara Espinosa, Enrique Clotet, Bonaventura Martinez-Picado, Javier Cerezuela, Pablo Soria, Ainara Marquez-Rodas, Ivan Mandala, Mario Berrocal, Alfonso J Immunother Cancer Position Article and Guidelines Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities. BMJ Publishing Group 2021-03-28 /pmc/articles/PMC8009216/ /pubmed/33782108 http://dx.doi.org/10.1136/jitc-2020-001664 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Position Article and Guidelines
Gonzalez-Cao, Maria
Puertolas, Teresa
Riveiro, Mar
Muñoz-Couselo, Eva
Ortiz, Carolina
Paredes, Roger
Podzamczer, Daniel
Manzano, Jose Luis
Molto, Jose
Revollo, Boris
Carrera, Cristina
Mateu, Lourdes
Fancelli, Sara
Espinosa, Enrique
Clotet, Bonaventura
Martinez-Picado, Javier
Cerezuela, Pablo
Soria, Ainara
Marquez-Rodas, Ivan
Mandala, Mario
Berrocal, Alfonso
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title_full Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title_fullStr Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title_full_unstemmed Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title_short Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
title_sort cancer immunotherapy in special challenging populations: recommendations of the advisory committee of spanish melanoma group (gem)
topic Position Article and Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009216/
https://www.ncbi.nlm.nih.gov/pubmed/33782108
http://dx.doi.org/10.1136/jitc-2020-001664
work_keys_str_mv AT gonzalezcaomaria cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT puertolasteresa cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT riveiromar cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT munozcouseloeva cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT ortizcarolina cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT paredesroger cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT podzamczerdaniel cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT manzanojoseluis cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT moltojose cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT revolloboris cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT carreracristina cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT mateulourdes cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT fancellisara cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT espinosaenrique cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT clotetbonaventura cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT martinezpicadojavier cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT cerezuelapablo cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT soriaainara cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT marquezrodasivan cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT mandalamario cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT berrocalalfonso cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem
AT cancerimmunotherapyinspecialchallengingpopulationsrecommendationsoftheadvisorycommitteeofspanishmelanomagroupgem